PHGUF Stock UPDATES Pharming Grp Nv Leid (PHGUF) 0.6399 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pharming Grp Nv Leid (PHGUF) 0.6399 $PHGUF

Pancreatitis - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8kdxqj/pancreatitis) has announced the addition of the "Pancreatitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pancreatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatitis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pancreatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pancreatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - GlaxoSmithKline plc - Pharming Group N.V. - D-Pharm Ltd. - AIM Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/8k...ncreatitis

Pharming Reports On Preliminary Financial Results 2013
Thomson Reuters ONE - Thu Mar 06, 12:00AM CST
- Revenues and other income decreased to EUR7.0 million (2012: EUR10.9 million) mainly as a result from lower license fees as 2012 included receipt of a EUR7.9 million milestone from our US partner Santarus for successful completion of study 1310 while 2013 included a EUR3.8 milestone from Santarus for acceptance for review of the BLA for Ruconest by the US FDA. Sales in 2013 increased to EUR0.9 million (2012: EUR0.8 million).

PHARMING AND SALIX ANNOUNCE EXTENSION OF PDUFA ACTION DATE FOR RUCONEST(r)
GlobeNewswire - Mon Feb 24, 12:12AM CST
Pharming Group NV (NYSE Euronext HARM) and Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that the Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) Action Date to July 16, 2014 for the Company's Biologics License Application (BLA) for the investigational drug RUCONEST(R) (recombinant human C1 esterase inhibitor) 50 IU/kg. Pharming and Salix are seeking U.S. marketing approval of RUCONEST for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE).

Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013 Research Report
M2 - Thu Jan 23, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/6c4qdd/fibrinogen) has announced the addition of the "Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013" report to their offering. 'Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency). Scope - A snapshot of the global therapeutic scenario for Fibrinogen Deficiency (Factor I Deficiency). - A review of the Fibrinogen Deficiency (Factor I Deficiency) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fibrinogen Deficiency (Factor I Deficiency) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Fibrinogen Deficiency (Factor I Deficiency) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Biotest AG Pharming Group N.V. Octapharma AG LFB S.A. China Biologic Products, Inc. For more information visit http://www.researchandmarkets.com/research/6c4qdd/fibrinogen About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Time for investors to move out of high-carbon assets, says UN climate change official
M2 - Thu Jan 16, 4:02AM CST
The top United Nations climate change official today urged investors to accelerate the greening of their portfolios as a crucial step towards a low-carbon economy that can better cope with the threats, and seize the opportunities from, climate change.

Market Research: Hereditary Angioedema (HAE) - Pipeline Review, H2 2013
M2 - Tue Dec 10, 2:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/x8rgxd/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) - Pipeline Review, H2 2013" report to their offering. 'Hereditary Angioedema (HAE) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hereditary Angioedema (HAE), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE). Scope - A snapshot of the global therapeutic scenario for Hereditary Angioedema (HAE). - A review of the Hereditary Angioedema (HAE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hereditary Angioedema (HAE) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Isis Pharmaceuticals, Inc. Pharming Group N.V. Dyax Corp. ViroPharma Incorporated BioCryst Pharmaceuticals, Inc. CSL Limited iBio, Inc. For more information visit http://www.researchandmarkets.com/research/x8rgxd/hereditary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Hemophilia - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rvbm6c/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H2 2013" report to their offering. 'Hemophilia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Scope - A snapshot of the global therapeutic scenario for Hemophilia. - A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Biogen Idec Inc. AstraZeneca PLC Nektar Therapeutics Cangene Corporation Lentigen Corporation Sangamo BioSciences, Inc. Pharming Group N.V. Novo Nordisk A/S BioMarin Pharmaceutical Inc. Chugai Pharmaceutical Co. Ltd Dong-A Pharmaceutical Co., Ltd. GTC Biotherapeutics, Inc. Octapharma AG Pain Therapeutics, Inc. Pfizer Inc. Bayer AG Living Cell Technologies Limited PROLOR Biotech, Inc. ReGenX Biosciences, LLC Alnylam Pharmaceuticals, Inc CSL Limited and many more... For more information visit http://www.researchandmarkets.com/research/rvbm6c/hemophilia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Hemophilia A - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Hemophilia
M2 - Wed Sep 04, 12:25PM CDT
Research and Markets (http://www.researchandmarkets.com/research/v3889m/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Hemophilia A - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia A, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia A. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Hemophilia A. - A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia A pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Cangene Corporation - Lentigen Corporation - Sangamo BioSciences, Inc. - Pharming Group N.V. - Novo Nordisk A/S - BioMarin Pharmaceutical Inc. - Dong-A Pharmaceutical Co., Ltd. - Octapharma AG - Pfizer Inc. - Bayer AG - PROLOR Biotech, Inc. - ReGenX Biosciences, LLC - Amarna Therapeutics B.V. - EpiVax, Inc. - Expression Therapeutics LLC - Asklepios BioPharmaceutical, Inc. - Amunix, Inc. - PolyTherics Limited - Celtic Pharmaceutical Holdings L.P. For more information visit http://www.researchandmarkets.com/research/v3...mophilia_a About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Transplantation - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2563g/transplantation) has announced the addition of the "Transplantation - Pipeline Review, H2 2013" report to their offering. 'Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transplantation. Scope - A snapshot of the global therapeutic scenario for Transplantation. - A review of the Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Hospira, Inc. F. Hoffmann-La Roche Ltd. Kyowa Hakko Kirin Co., Ltd. Osiris Therapeutics, Inc. Athersys, Inc. GlaxoSmithKline plc Quark Pharmaceuticals, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc Pharming Group N.V. Vectura Group plc BioLineRx, Ltd. Novartis AG Isotechnika Pharma Inc. Samyang Corporation Astellas Pharma Inc. ViroPharma Incorporated Cell Therapeutics, Inc. Genmab A/S Exelixis, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/s2...plantation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Pharming Redeems Final Tranche of Convertible Bond for Cash
Marketwire - Thu Aug 29, 9:20AM CDT
Biotech company Pharming Group NV ("Pharming" or "the Company" (NYSE Euronext: PHARM) today announced that it decided to redeem the seventh and final tranche of its EUR16.35 million convertible bond for cash. A total of EUR 2,354,465 will be paid in cash to the bondholders on 1 October 2013 under the terms and conditions of the bond, serving as a final redemption and interest payment.

Pharming redeems final tranche of convertible bond for cash
Thomson Reuters ONE - Thu Aug 29, 9:12AM CDT
No additional shares to be issued for final tranche

Pharming reports on financial results first half year 2013
Marketwire - Thu Aug 01, 12:10AM CDT
Leiden, The Netherlands, 1 August 2013. Biotech company Pharming Group NV ("Pharming" or "the Company" (NYSE Euronext: PHARM) today published its financial report for the six months ended 30 June 2013.

Pharming and Santarus announce poster presentation of pivotal clinical data for RUCONEST(R) (recombinant human C1 esterase inhibitor)
Marketwire - Tue Jun 25, 12:56AM CDT
Pharming Group NV (NYSE Euronext: PHARM) and Santarus, Inc. (NASDAQ: SNTS), announced that new data from a pivotal Phase III clinical study with RUCONEST(R) (recombinant human C1 esterase inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) were featured in a poster presentation yesterday at the European Academy of Allergy and Clinical Immunology (EAACI) & World Allergy Organization (WAO) World Allergy & Asthma Congress in Milan, Italy. The data indicate that the time to beginning of relief of symptoms in patients experiencing an acute attack of HAE was statistically significantly shorter with RUCONEST compared with placebo.

Pharming and Santarus announce poster presentation of pivotal clinical data for RUCONEST® (recombinant human C1 esterase inhibitor)
Thomson Reuters ONE - Tue Jun 25, 12:00AM CDT
LEIDEN, Netherlands and SAN DIEGO (June 25, 2013) - Pharming Group NV (NYSE Euronext: PHARM) and Santarus, Inc. (NASDAQ: SNTS), announced that new data from a pivotal Phase III clinical study with RUCONEST® (recombinant human C1 esterase inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) were featured in a poster presentation yesterday at the European Academy of Allergy and Clinical Immunology (EAACI) & World Allergy Organization (WAO) World Allergy & Asthma Congress in Milan, Italy. The data indicate that the time to beginning of relief of symptoms in patients experiencing an acute attack of HAE was statistically significantly shorter with RUCONEST compared with placebo.

Santarus and Pharming announce FDA acceptance for review of RUCONEST (recombinant human C1 esterase inhibitor) Biologics License Application
Thomson Reuters ONE - Tue Jun 18, 12:00AM CDT
SAN DIEGO & Leiden, The Netherlands (June 18, 2013) - Santarus, Inc. (NASDAQ: SNTS) and Pharming Group NV (NYSE Euronext: PHARM) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Biologics License Application (BLA) for the investigational drug RUCONEST® (recombinant human C1 esterase inhibitor) 50 IU/kg. Santarus and Pharming are seeking U.S. marketing approval of RUCONEST for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE). The FDA indicated that as part of its review it plans to present the BLA to the Blood Products Advisory Committee. Pursuant to the Prescription Drug User Fee Act (PDUFA) guidelines, Santarus and Pharming expect the FDA will complete its review or otherwise respond to the RUCONEST BLA by April 16, 2014.

Pharming Group reduces loss in first quarter 2013
M2 - Thu May 16, 7:44AM CDT
Biotech company Pharming Group NV (NYSE HARM) (Euronext: PHARM) reported today a net loss of EUR5.4m for the first quarter of 2013, ended 31 March 2013.

Pharming reports on financial results first quarter 2013
Marketwire - Thu May 16, 12:07AM CDT
Biotech company Pharming Group NV ("Pharming" or "the Company" (NYSE Euronext: PHARM) today published its financial report for the three months ended 31 March 2013.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

XKIG Bolsters Northwest with Jensen's Acquisition

Updated Category News Views 44

Stepping Up the Game in the Pacific Northwest Well, here we see another classic example of a shrewd move in the infrastructure sector. XKIG, a name known to those who keep an eye on critical infrastructure services for utilities, has decided to widen its footprint with a strategic grab of Jensen's Tree Service, Inc. They’re setting up shop even deeper in the Pacific...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 193

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
NVIDIA Faces Fraud Suit: Investors Called to Action

Updated Category News Views 85

NVIDIA and the Quest for Accountability Nothing screams chaos in the market louder than a securities fraud lawsuit hitting the headlines. Investors currently eyeballing NVIDIA Corporation (NASDAQ: NVDA) are in for a wild ride. Yep, you heard it right—NVIDIA is smack in the middle of a class action lawsuit. They're being accused of misleading the market about some shady...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 74

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 104

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 100

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 246

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 88

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 126

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading

Top 5 Most Recently Viewed Articles

RegScale Secures FedRAMP High Authorization: A Game-Changer

Updated Category News Views 263

RegScale Secures FedRAMP High Authorization RegScale, utilizing its innovative Continuous Controls Monitoring platform, has reached the notable milestone of obtaining FedRAMP High Authorization, demonstrating a significant advancement in compliance and risk management within the government sector. This achievement showcases RegScale's commitment to enhancing security...

Continue Reading
SiriusXM Improves Financial Guidance Amid Digital Growth

Updated Category News Views 214

SiriusXM Holdings Inc Experiences Stock Surge SiriusXM Holdings Inc (NASDAQ:SIRI) saw its stock prices climb significantly following the release of its fiscal third-quarter results. Investors responded positively as the company’s future outlook showed promise for expansion. Positive Financial Results The report revealed a subscriber revenue of $1.63 billion for the...

Continue Reading
Explore Top Free AI Image Translators for Your Needs

Updated Category News Views 288

Unlocking the Power of Image Translation Translating text from images is a crucial task in today’s digital world. Whether you need to read signs, understand menus, interpret social media posts, or analyze product reviews, having a reliable image translator can make a significant difference. The right tools not only improve accuracy but also support multiple languages,...

Continue Reading
Exciting Collaboration Unveiled: REESE'S and OREO Join Forces

Updated Category News Views 240

An Exciting New Collaboration The anticipation has been palpable among fans of REESE'S and OREO, and now, the moment has arrived. These iconic brands, celebrated for their unique flavors, are thrilled to present a delectable collaboration that combines their most popular offerings. This partnership responds directly to the enthusiasm and demand expressed by fans....

Continue Reading
Innovative Clinical Research Enhances Care for Cancer Patients

Updated Category News Views 440

Innovative Research at Florida Cancer Specialists Clinical research at Florida Cancer Specialists & Research Institute is making significant strides in expanding treatment options for patients dealing with gastrointestinal and genitourinary cancers. This knowledgeable institute is at the forefront of developing and presenting vital research that contributes to improved...

Continue Reading